Literature DB >> 26378095

Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

Philip J Barter1, Fatiha Tabet2, Kerry-Anne Rye2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26378095      PMCID： PMC4617391          DOI： 10.1194/jlr.C063768

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  25 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.

Authors:  John S Millar; Margaret E Brousseau; Margaret R Diffenderfer; P Hugh R Barrett; Francine K Welty; Aisha Faruqi; Megan L Wolfe; Chorthip Nartsupha; Andres G Digenio; James P Mancuso; Gregory G Dolnikowski; Ernst J Schaefer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-30       Impact factor: 8.311

3.  Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Authors:  Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

4.  Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Authors:  Laurent Yvan-Charvet; Fumihiko Matsuura; Nan Wang; Mark J Bamberger; Tu Nguyen; Franz Rinninger; Xian-Cheng Jiang; Charles L Shear; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-22       Impact factor: 8.311

5.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

6.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Authors:  Ahmed Zaid; Anna Roubtsova; Rachid Essalmani; Jadwiga Marcinkiewicz; Ann Chamberland; Josée Hamelin; Michel Tremblay; Hélène Jacques; Weijun Jin; Jean Davignon; Nabil G Seidah; Annik Prat
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

7.  Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

Authors:  Hyun Jeong Jeong; Hyun-Sook Lee; Kyung-Sup Kim; Yoon-Kyoung Kim; Dojun Yoon; Sahng Wook Park
Journal:  J Lipid Res       Date:  2007-10-05       Impact factor: 5.922

8.  The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.

Authors:  Nasha Nassoury; Daniel A Blasiole; Angie Tebon Oler; Suzanne Benjannet; Josée Hamelin; Vivianne Poupon; Peter S McPherson; Alan D Attie; Annik Prat; Nabil G Seidah
Journal:  Traffic       Date:  2007-04-25       Impact factor: 6.215

9.  Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor.

Authors:  Sha Huang; Lisa Henry; Yiu Kee Ho; Henry J Pownall; Gabby Rudenko
Journal:  J Lipid Res       Date:  2009-08-11       Impact factor: 5.922

10.  SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element.

Authors:  X Hua; C Yokoyama; J Wu; M R Briggs; M S Brown; J L Goldstein; X Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205
View more
  1 in total

Review 1.  Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Authors:  Theodosios D Filippatos; Anastazia Kei; Moses S Elisaf
Journal:  Diseases       Date:  2017-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.